SymBio Pharmaceuticals LtdOTC Pink - Current Information:SYMQY
- LAST PRICE1.2100
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.3200/ 5
- Ask / Lots89.7300/ 1
- Open / Previous Close--- / 1.2100
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
Oct 31, 2024
DJ SymBio Pharmaceuticals 9-Mos Loss Y2.85B Vs Loss Y788.00M, from 2:30AM ET on Thursday Oct 31, 2024 by Dow Jones
2:30AM ET on Thursday Oct 31, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
SymBio Pharmaceuticals Ltd | 71.7M | -2.0x | --- |
Neutra Corp | 291.8K | -1.7x | --- |
Vitalibis Inc | 26.8K | 0.0x | --- |
Cannabis Suisse Corp | 311.0K | -0.9x | --- |
Omni Health Inc | 1.1K | 0.0x | --- |
Earth Life Sciences Inc | 100.0K | -0.2x | --- |
Company Information
SymBio Pharmaceuticals Limited is a Japan-based pharmaceutical company. Along with medicine specialists, contract research organizations (CROs) and other pharmaceutical companies, the Company is engaged in the design and operation of clinical tests, the manufacture and sale of new drugs specializing in three therapeutic areas: cancer, blood diseases and autoimmune diseases. The Company develops new medicines using chemical compounds proofed by preclinical tests and clinical tests. The Company manufactures and sells medicines through domestic and foreign pharmaceutical companies. The Company's pipelines include anticancer drugs, such as SyB L-0501, SyB L-1101 and SyB C-1101.
Contact Information
- Headquarters
- Toranomon 30 Mori Bldg. 3-2-2, ToranomonMINATO-KU, TKY, Japan 105-0001
- Phone
- ---
- Fax
- ---
Executives
- President, Executive President, Chief Executive Officer, Representative Director
- Fuminori Yoshida
- Chief Financial Officer, Managing Executive Officer
- Takaaki Fukushima
- Director of Finance and Accounting
- Ryuji Azeyanagi
- Executive Vice President, Chief Operating Officer, Director
- Hirotaka Ito
- Managing Executive Officer
- Shunichi Sasaki
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $71.7M |
|---|---|
Revenue (TTM) | $19.8M |
Shares Outstanding | 45.9M |
SymBio Pharmaceuticals Ltd does not pay a dividend. | |
Beta | --- |
EPS | $-0.60 |
Book Value | $1.11 |
P/E Ratio | -2.0x |
Price/Sales (TTM) | 3.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -126.24% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
